Publications by authors named "A A Vijayan"

Hydroxyapatite (HA), the main inorganic bone component, is the most widely researched bioceramic for bone repair. This paper presents a comprehensive review of recent advancements in HA synthesis methods and their integration into additive manufacturing (AM) processes. Synthesis methodologies discussed include wet, dry, and biomimetic routes, emphasizing their impact on tailoring the physicochemical properties of HA for biomedical applications.

View Article and Find Full Text PDF
Article Synopsis
  • High-dose methotrexate (MTX) can lead to serious complications like acute kidney injury (AKI), neutropenia, and liver damage, but glucarpidase, an enzyme that breaks down MTX, shows potential benefits.
  • In a study of 708 patients with MTX-AKI across 28 cancer centers, those receiving glucarpidase had a significantly higher chance of kidney recovery and faster recovery times compared to those who did not receive the treatment.
  • Additionally, glucarpidase treatment was associated with lower rates of severe neutropenia and liver enzyme elevation, but there was no notable difference in mortality rates between the two groups.
View Article and Find Full Text PDF

This study investigated major contributors of the particulate organic matter (POM) using stable isotope ratios of particulate organic carbon (δC) and its relationship with phytoplankton composition during three seasons across six coast-offshore transects in the eastern Arabian Sea (EAS). Results revealed significant spatiotemporal variations, with elevated δC in coastal waters during the winter and summer monsoon (-22.40 ± 1.

View Article and Find Full Text PDF

Newly approved subunit and mRNA vaccines for respiratory syncytial virus (RSV) demonstrate effectiveness in preventing severe disease, with protection exceeding 80% primarily through the generation of antibodies. An alternative vaccine platform called self-amplifying RNA (saRNA) holds promise in eliciting humoral and cellular immune responses. We evaluate the immunogenicity of a lipid nanoparticle (LNP)-formulated saRNA vaccine called SMARRT.

View Article and Find Full Text PDF